OncoMatch/Clinical Trials/NCT06311981
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
Is NCT06311981 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for non-small cell lung cancer.
To observe the effect and toxicity of carbon ion radiotherapy on local advanced non-small cell lung cancer over 75 years old patients. Systemic therapy could be targeted therapy, chemotherapy or immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIB, IIIC
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: bevacizumab (bevacizumab)
Exception: only if squamous cell carcinoma and treated before carbon ion radiotherapy
Patient with squamous cell carcinoma was treated with bevacizumab before carbon ion radiotherapy
Cannot have received: chest radiation therapy
Chest radiation therapy or radioactive particle implantation history
Lab requirements
Blood counts
ANC ≥1.5 x 10^9/L, platelet count ≥80 x 10^9/L, hemoglobin ≥9 g/dL
Kidney function
serum creatinine ≤1.5x ULN or CrCl ≥50 ml/min, urinary protein <2+ (if ≥2+, 24h urine protein ≤1g)
Liver function
total bilirubin <1.5x ULN, AST/ALT <2x ULN
Cardiac function
no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease or other complications that may affect radiotherapy
Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109/L, platelet count ≥80 x 109/L, hemoglobin ≥9 g/dL 2). Lung function: FEV1>25%, DLCO>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin <1.5 times the upper limit of normal value, and AST, ALT<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml /min, and urinary protein <2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06311981 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bevacizumab, chest radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IIB or IIIC is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages